| Ytd | 45.45% | |
| 1y | 62.21% |
| Open | 3.54 | Prev Close | 3.47 | Low | 3.41 | High | 3.54 | Mkt Cap | 200.67M |
| Vol | 320.26K | Avg Vol | 367.72K | EPS | -1.14 | P/E | N/A | Forward P/E | N/A |
| Beta | 0.92 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 4.27 | 200-d Avg | 3.79 | 1yr Est | 0.00 |
WHWK News
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) has been given a consensus rating of "
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Pote
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Poten
Stifel analyst Dara Azar initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Buy ra
Shares of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) have been assigned an averag
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Confere
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medi
MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clini
Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum inve
The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.20) per share which beat the a
Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track
Leerink Partners analyst Jonathan Chang initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK
BOSTON & MORRISTOWN, N.J.--(BUSINESS WIRE)-- #ADC--Biocytogen (SSE: 688796; HKEX: 02315) and Whiteha
Whitehawk Therapeutics Presents RealâWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinica
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is posit
22,321,887 Shares of Common Stock This prospectus relates to the offer and resale from time to time
MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, I
MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic
MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic
Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] afte
Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (NASDAQ:WHWK), a clinica
MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "White
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.32) per share which missed the
Top large-cap losers last week included IonQ, Tempus AI, AeroVironment, Astera Labs, Nebius, Kratos,